The data in Figure 1B demonstrate that an increased serum level of PD-L1 was more likely to be in patients whose tumor expressing the CD44high/CD24low phenotype and with tumors presenting the loss of PTEN and high pAkt expression. The gene discussed is PTEN; the disease is neoplasm.